A double-blind clinical evaluation of penfluridol (R 16 341) as a maintenance therapy in schizophrenia.
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D006846:Hydrocarbons, Halogenated / Q000627:therapeutic use; D007406:Interview, Psychological; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D013997:Time Factors; D014050:Toluene / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D006846:Hydrocarbons, Halogenated; D010880:Piperidines; D010919:Placebos; D014149:Tranquilizing Agents; D014050:Toluene; D006220:Haloperidol